Combat Medical reports 68% high-grade recurrence-free survival at 12 months in BCG-unresponsive non-muscle invasive bladder cancer study
Combat Medical (Combat), a medical device company optimizing the delivery and efficacy of cancer therapeutics, today announced new real-world data showing 68% high-grade recurrence-free survival (HG-RFS) at 12 months in patients with Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) after hyperthermic intravesical chemotherapy (HIVEC®) with mitomycin C.
Read original article on The Medical News →Related news
-
Childhood cancer cells shape-shift to spread without genetic mutations
United Kingdom
-
AI assesses what really matters to people in health care—well-being
United Kingdom
-
Early trial results suggest potential new treatment for stiff person syndrome
United Kingdom
-
US youths see nearly 4,000 food marketing messages on digital media each year
United Kingdom
-
A brief history of the food pyramid – and its many false starts
Australia
-
Fish Stocks Thrive Thanks to This Pink Seaweed and Locals Who Protected It
United Kingdom
-
It takes a neighborhood to keep kids active
United Kingdom
-
Two-year study will examine how gender-affirming hormone therapy affects energy use and blood vessel function
United Kingdom